PL2623507T3 - Pochodna kwasu morfolinonukleinowego - Google Patents
Pochodna kwasu morfolinonukleinowegoInfo
- Publication number
- PL2623507T3 PL2623507T3 PL11829283T PL11829283T PL2623507T3 PL 2623507 T3 PL2623507 T3 PL 2623507T3 PL 11829283 T PL11829283 T PL 11829283T PL 11829283 T PL11829283 T PL 11829283T PL 2623507 T3 PL2623507 T3 PL 2623507T3
- Authority
- PL
- Poland
- Prior art keywords
- nucleic acid
- acid derivative
- morpholino nucleic
- morpholino
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010220865 | 2010-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2623507T3 true PL2623507T3 (pl) | 2017-03-31 |
Family
ID=45893168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11829283T PL2623507T3 (pl) | 2010-09-30 | 2011-09-29 | Pochodna kwasu morfolinonukleinowego |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8969551B2 (pl) |
| EP (1) | EP2623507B1 (pl) |
| JP (1) | JP5831455B2 (pl) |
| KR (1) | KR101764462B1 (pl) |
| CN (1) | CN103154009B (pl) |
| CA (1) | CA2813183C (pl) |
| CY (1) | CY1118435T1 (pl) |
| DK (1) | DK2623507T3 (pl) |
| ES (1) | ES2607603T3 (pl) |
| HR (1) | HRP20170028T1 (pl) |
| HU (1) | HUE030292T2 (pl) |
| LT (1) | LT2623507T (pl) |
| PL (1) | PL2623507T3 (pl) |
| PT (1) | PT2623507T (pl) |
| RS (1) | RS55610B1 (pl) |
| SI (1) | SI2623507T1 (pl) |
| SM (2) | SMT201700038T1 (pl) |
| WO (1) | WO2012043730A1 (pl) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| EP3133160B1 (en) | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
| KR101981705B1 (ko) * | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| US9920085B2 (en) | 2012-03-20 | 2018-03-20 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| CN102702265A (zh) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | 一种固相合成磷酰二胺吗啉代寡核苷酸及方法 |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| HK1220154A1 (zh) | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| JP6477464B2 (ja) | 2013-05-24 | 2019-03-06 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| AU2014317961B2 (en) | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
| CA2948568A1 (en) | 2014-05-19 | 2015-11-26 | David Greenberg | Antisense antibacterial compounds and methods |
| JP6673211B2 (ja) | 2014-10-14 | 2020-03-25 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| WO2016108930A2 (en) * | 2014-12-31 | 2016-07-07 | Geller Bruce L | Antisense antibacterial compounds and methods |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| KR102644053B1 (ko) | 2015-05-19 | 2024-03-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 펩티드 올리고뉴클레오티드 콘주게이트 |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| RS62930B1 (sr) | 2015-08-05 | 2022-03-31 | Eisai R&D Man Co Ltd | Postupak za pripremu suštinski dijastereomerno čistog fosforodiamidatnog oligomera, fosforodiamidatni oligomer proizveden takvim postupkom i farmaceutska kompozicija koja sadrži fosforodiamidatni oligomer |
| JP2018530560A (ja) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス, インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
| EA201891419A1 (ru) | 2015-12-15 | 2019-01-31 | Сарепта Терапьютикс, Инк. | Пептид-олигонуклеотидные конъюгаты |
| US11142764B2 (en) | 2015-12-23 | 2021-10-12 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11060089B2 (en) | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| JP7042255B2 (ja) | 2016-04-29 | 2022-03-25 | サレプタ セラピューティクス, インコーポレイテッド | ヒトlmnaを標的にするオリゴヌクレオチド類縁体 |
| MX390906B (es) | 2016-05-24 | 2025-03-21 | Sarepta Therapeutics Inc | Procesos para preparar oligómeros de morfolino fosforodiamidato. |
| US10947533B2 (en) | 2016-05-24 | 2021-03-16 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MX384727B (es) | 2016-05-24 | 2025-03-14 | Sarepta Therapeutics Inc | Procesos para preparar oligómeros |
| MA45158A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Composition pharmaceutique comprenant de l'éteplirsen |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| TWI737736B (zh) | 2016-05-24 | 2021-09-01 | 美商薩羅塔治療公司 | 製備磷醯二胺嗎啉代寡聚物之方法 |
| CA3024153A1 (en) | 2016-06-30 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| AU2017330276B2 (en) * | 2016-09-20 | 2022-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry |
| ES2994451T3 (en) | 2017-04-20 | 2025-01-24 | Atyr Pharma Inc | Compositions for treating lung inflammation |
| TWI812647B (zh) | 2017-09-25 | 2023-08-21 | 美商薩羅塔治療公司 | 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程 |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| US11560401B2 (en) | 2018-05-10 | 2023-01-24 | Nippon Shinyaku Co., Ltd. | Method for preparing oligonucleic acid compound |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| EP4059943A4 (en) | 2019-11-13 | 2024-01-31 | Nippon Shinyaku Co., Ltd. | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND |
| EP4059944A4 (en) * | 2019-11-13 | 2024-04-10 | Nippon Shinyaku Co., Ltd. | METHOD FOR PREPARING AN OLIGONUCLICE ACID COMPOUND |
| EP4182315A4 (en) * | 2020-07-10 | 2024-07-03 | Changzhou Syntheall Pharmaceuticals Co., Ltd. | Processes for preparing oligonucleotides |
| CN117279926A (zh) * | 2021-04-28 | 2023-12-22 | 日本新药株式会社 | 低聚核酸化合物的制造方法 |
| WO2022232478A1 (en) | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| US12378267B2 (en) | 2021-06-17 | 2025-08-05 | Entrada Therapeutics, Inc. | Synthesis of FMOC-protected morpholino monomers and oligomers |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| KR20240129006A (ko) * | 2021-12-27 | 2024-08-27 | 니뽄 신야쿠 가부시키가이샤 | 올리고 핵산 화합물의 제조 방법 |
| KR20240155905A (ko) * | 2022-03-01 | 2024-10-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 비스-보호된 활성화된 구아닌 단량체 |
| EP4493693A1 (en) | 2022-03-17 | 2025-01-22 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| US20250289851A1 (en) | 2022-04-22 | 2025-09-18 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| EP4590311A2 (en) | 2022-09-21 | 2025-07-30 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312834T1 (de) | 1989-12-20 | 2005-12-15 | Avi Biopharma Inc | Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten |
| JP2005255530A (ja) * | 2004-03-09 | 2005-09-22 | Japan Science & Technology Agency | 2−チオウリジン誘導体 |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US8076476B2 (en) * | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| MX2010004955A (es) * | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
-
2011
- 2011-09-29 CN CN201180047487.3A patent/CN103154009B/zh active Active
- 2011-09-29 WO PCT/JP2011/072407 patent/WO2012043730A1/ja not_active Ceased
- 2011-09-29 RS RS20170057A patent/RS55610B1/sr unknown
- 2011-09-29 DK DK11829283.8T patent/DK2623507T3/da active
- 2011-09-29 CA CA2813183A patent/CA2813183C/en active Active
- 2011-09-29 US US13/876,194 patent/US8969551B2/en active Active
- 2011-09-29 PT PT118292838T patent/PT2623507T/pt unknown
- 2011-09-29 JP JP2012536551A patent/JP5831455B2/ja active Active
- 2011-09-29 SM SM20170038T patent/SMT201700038T1/it unknown
- 2011-09-29 LT LTEP11829283.8T patent/LT2623507T/lt unknown
- 2011-09-29 ES ES11829283.8T patent/ES2607603T3/es active Active
- 2011-09-29 HU HUE11829283A patent/HUE030292T2/en unknown
- 2011-09-29 HR HRP20170028TT patent/HRP20170028T1/hr unknown
- 2011-09-29 KR KR1020137011017A patent/KR101764462B1/ko active Active
- 2011-09-29 SI SI201131069A patent/SI2623507T1/sl unknown
- 2011-09-29 EP EP11829283.8A patent/EP2623507B1/en active Active
- 2011-09-29 PL PL11829283T patent/PL2623507T3/pl unknown
-
2017
- 2017-01-10 CY CY20171100027T patent/CY1118435T1/el unknown
- 2017-01-19 SM SM201700038T patent/SMT201700038B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130143045A (ko) | 2013-12-30 |
| SMT201700038B (it) | 2017-03-08 |
| EP2623507B1 (en) | 2016-11-02 |
| SMT201700038T1 (it) | 2017-03-08 |
| CA2813183A1 (en) | 2012-04-05 |
| JP5831455B2 (ja) | 2015-12-09 |
| US20130197220A1 (en) | 2013-08-01 |
| RS55610B1 (sr) | 2017-06-30 |
| CN103154009B (zh) | 2015-06-10 |
| SI2623507T1 (sl) | 2017-04-26 |
| HRP20170028T1 (hr) | 2017-03-24 |
| EP2623507A4 (en) | 2014-03-19 |
| CY1118435T1 (el) | 2017-06-28 |
| ES2607603T3 (es) | 2017-04-03 |
| DK2623507T3 (da) | 2017-01-02 |
| KR101764462B1 (ko) | 2017-08-02 |
| US8969551B2 (en) | 2015-03-03 |
| CA2813183C (en) | 2017-09-19 |
| JPWO2012043730A1 (ja) | 2014-02-24 |
| EP2623507A1 (en) | 2013-08-07 |
| WO2012043730A1 (ja) | 2012-04-05 |
| CN103154009A (zh) | 2013-06-12 |
| PT2623507T (pt) | 2016-12-23 |
| LT2623507T (lt) | 2017-01-25 |
| HUE030292T2 (en) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2623507T1 (sl) | Derivati morfolino-nukleinske kisline | |
| GB2494239B (en) | Nucleic acid amplification | |
| PL2612917T3 (pl) | Antysensowy kwas nukleinowy | |
| DK2922554T3 (en) | Terminalt modificeret rna | |
| IL231983B (en) | Dna containing tricyclo-phosphorothioate | |
| SG10201802883UA (en) | Nucleic acid amplification | |
| EP2592081A4 (en) | TETRAHYDROCARBOLINDERIVAT | |
| GB201204407D0 (en) | Nucleic acid molecule | |
| GB201020095D0 (en) | Nucleic acid preparation method | |
| IL223642A (en) | Inorganic elements to enhance gene expression | |
| ZA201304998B (en) | Dna expression construct | |
| ZA201206793B (en) | Nucleic acid complexes | |
| GB2479833B (en) | Modified nucleotides | |
| ZA201400918B (en) | Pyrrolidine-3-ylacetic acid derivative | |
| GB201120989D0 (en) | Genetic test | |
| EP2655365A4 (en) | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | |
| EP2594592A4 (en) | COMPLEX (NUCLEIC ACID) -POLYSACCHARIDE | |
| GB201107286D0 (en) | Nucleic acid preparation | |
| GB201001940D0 (en) | Nucleic acid isolation | |
| GB201105387D0 (en) | Nucleic acid probes | |
| GB201009654D0 (en) | Nucleic acid methyltransferase | |
| AU2011902654A0 (en) | Nucleic acid complex | |
| GB201014572D0 (en) | Genetic tests | |
| GB201004862D0 (en) | DNA amplification | |
| GB201115254D0 (en) | Genetic test |